Bayer/Ionis Advance Next-Generation Antithrombotic After Positive Clinical Results
And Bayer Sets Up Artificial Intelligence Center In The UK
In a collaboration with Ionis Pharmaceuticals, Bayer is pressing ahead with Phase II clinical studies of an antisense molecule designed to reduce Factor XI production and prevent thrombosis.
